Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis

BACKGROUND: Bladder cancer is the most common malignant tumor of the urinary system. Surgical resection and chemotherapy are the two mainstream treatments for bladder cancer. However, the outcomes are not satisfactory for patients with advanced bladder cancer. There is a need to further explore more...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenlong, He, Xin, Yin, Haoli, Cao, Wenmin, Lin, Tingsheng, Chen, Wei, Diao, Wenli, Ding, Meng, Hu, Hao, Mo, Wenjing, Zhang, Qing, Guo, Hongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284842/
https://www.ncbi.nlm.nih.gov/pubmed/35836291
http://dx.doi.org/10.1186/s13045-022-01312-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284842/
https://www.ncbi.nlm.nih.gov/pubmed/35836291
http://dx.doi.org/10.1186/s13045-022-01312-5

Ejemplares similares